Form 4: Iovance Biotherapeutics Executive Raj K. Puri Reports Acquisition of Restricted Stock Units
SEC Form 4
Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reports the acquisition of 117,190 restricted stock units (RSUs) on March 5, 2025.
Summary
- On March 5, 2025, Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, acquired 117,190 Restricted Stock Units (RSUs).
- These RSUs represent a contingent right to receive one share of Iovance's common stock per unit.
- The RSUs will vest over three years, with one-third vesting on the one-year anniversary of the grant date.
- The remaining RSUs will vest in eight equal quarterly installments over the subsequent two years, starting with the first quarter after the one-year anniversary, provided the Reporting Person is still employed with the Issuer.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock unit acquisition.
Positives
- The vesting schedule incentivizes continued employment with Iovance Biotherapeutics.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the biopharmaceutical industry.
Stakeholder Impact
- The acquisition of RSUs by a key executive aligns their interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of transaction: Acquisition of Restricted Stock Units |
| 03/07/2025 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.